Pulmatrix Inc. (PULM)
NASDAQ: PULMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PULM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.64M
- EPS (TTM)
- -$1.20
- Dividend yield
- None
- 52-week range
- 1.06 – 4.94
- Day range
- 1.20 – 1.42
- Volume / Avg
- 90.74K / 35.45K
- Beta
- —
- Shares outstanding
- 3.65M
52-week range
PULM stock today
Shares of Pulmatrix (PULM) finished lower on Nov 20 at $1.27, a drop of 10.56% or $0.15 per share, versus the S&P 500's 3.70% decline. Volume was 2.6x the average at 90.74K shares, a sign of unusually heavy trading. At this level, PULM sits near the bottom of its 52-week range of $1.06 to $4.94: 74.3% below the high and 19.8% above the low.
Pulmatrix has posted a net loss over the last twelve months (EPS of -$1.20), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Pulmatrix
Company profilePulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Peter Ludlum CMA, MBA
- Headquarters
- Framingham, MA
- Employees
- 2
- IPO year
- 2014
- Website
- pulmatrix.com
Financial highlights
Full financialsPulmatrix reported a net loss of $5.2 million, compared with a loss of $9.6 million a year earlier. Diluted earnings per share came in at -$1.41.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | $7.81M | $7.30M | $6.07M | $5.17M |
| Growth | — | +6.96% | +20.21% | +17.45% | -59.09% |
| Net income | $-5.16M | $-9.56M | $-14.12M | $-18.84M | $-20.17M |
| EPS (diluted) | $-1.41 | $-2.62 | $-3.87 | $-5.46 | $-8.63 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 17, 2026
- EPS actual vs est.
- $-0.34 vs —
PULM news
All PULM news- Pulmatrix Q3 Loss Widens; Expects Eos SENOLYTIX Merger To Close In November; Stock UpNasdaqPULM, ET
- Pulmatrix, Inc. Reports Third Quarter 2026 Financial Results and Progress on Eos SENOLYTIX MergerNasdaqPULM, BF.A
- Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on MergerPR Newswire
- Pulmatrix, Inc. Stockholders Approve Merger-Related Proposals and Reverse Stock SplitNasdaqPULM, BIO.B
Pulmatrix peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BLRXBioLineRx Ltd. ADR | 0.9639 | -8.20% | $4.80M | vs PULM |
| PCSAProcessa Pharmaceuticals Inc. | 1.56 | -7.69% | $4.37M | vs PULM |
| CANFCan-Fite Biopharma Ltd ADR | 1.44 | -2.34% | $4.35M | vs PULM |
| SNGXSoligenix Inc. | 0.2201 | -8.29% | $5.14M | vs PULM |
| SCNXScienture Holdings Inc. | 2.28 | -6.45% | $4.07M | vs PULM |
| CNSPCNS Pharmaceuticals Inc. | 3.56 | -12.75% | $5.25M | vs PULM |
| LTRNLantern Pharma Inc. | 0.245 | -13.73% | $3.89M | vs PULM |
| UPCUniverse Pharmaceuticals Inc. Class A | 1.08 | -20.59% | $5.43M | vs PULM |
Indexes, lists and sector
Pulmatrix stock FAQ
What is Pulmatrix's stock price today?
PULM last traded at $1.27 as of Nov 20, 4:00 PM EST, down 10.56% on the day. Prices are delayed at least 15 minutes.
Who is Pulmatrix's CEO?
Mr. Peter Ludlum CMA, MBA is the chief executive officer of Pulmatrix Inc., which has about 2 employees.
What is the PULM 52-week high?
The 52-week high for PULM is $4.94 and the 52-week low is $1.06. The stock is currently 74.3% below its high.